Jul 2026· Journal of Materials Science· Vol 61, pp. 24874 - 24892· 0 citations· 38 references
TL;DR
In vivo animal experiments show that the drug-loaded scaffold significantly inhibits tumor recurrence and distant metastasis while exhibiting low chemotherapy drug toxicity and causing no damage to healthy tissues, making it a novel candidate for post-mastectomy prognosis in breast tumors and effective cancer treatment.
The data demonstrate that HNP platforms are a convincing, practically feasible approach to reducing post-surgical recurrence rates and enhancing patient outcomes.
Bogdan Mircea Măciuceanu Zărnescu, Denisa Nicoleta Mușat, Adelina-Gabriela Niculescu et al.· Nanomaterials· 3 citations
An autologous tumor cell-integrated microporous annealed particle scaffold co-delivering an immune adjuvant and an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor for tumor postoperative therapy is developed, establishing a paradigm that unifies personalized immunotherapy with personalized tissue repair, offering substa...
In vitro studies showed that the composite hydrogel displayed good biocompatibility and significantly inhibited MB49 bladder cancer cell proliferation, induced apoptosis, and suppressed migration and invasion, indicating that the HA-PBA/PVA hydrogel-liposome composite system is a promising localized therapeutic strateg...
Zi-Hao Chen, Jia-Xin Li, Hong Hu et al.· ACS Applied Bio Materials· 0 citations
This Janus-inspired patch is designed to bridge surgical resection and localized chemotherapy within a single intraoperative implant, and establishes an effective strategy that bridges surgery and intratumoral chemotherapy for effective postoperative PDAC control.
Xuan Pan, Xiao-Ming Wang, Qin Dang et al.· Materials Today Bio· 0 citations
Overall, the most clinically realistic direction is a staged and adaptable platform that provides early local tumor control while progressively supporting bone regeneration and structural reconstruction.
Xiaonan Wang, Aobo Zhang· International Journal of Bio...· 0 citations
The development of biocompatible and biodegradable drug delivery systems remains a major challenge in cancer therapy, particularly for the localized and sustained release of poorly soluble, unstable, and highly toxic compounds. 7‐Ethyl‐10‐hydroxycamptothecin (SN‐38), the active metabolite of irinotecan, offers superi...